Systemic insulin sensitivity pathways

Systemic insulin sensitivity pathways encompass the complex network of intracellular signaling events, primarily the PI3K/Akt and MAPK cascades, that mediate the body's response to insulin [NIH, Cell Signaling Technology]. These pathways are initiated by insulin binding to the insulin receptor, a tyrosine kinase that phosphorylates insulin receptor substrates (IRS), triggering downstream effectors that regulate glucose uptake via GLUT4 translocation, glycogen synthesis, and lipid metabolism [NIH, Nature Reviews]. Dysregulation of these pathways leads to insulin resistance, a hallmark of type 2 diabetes, metabolic syndrome, and obesity [StatPearls, NIH]. Therapeutic interventions like metformin and thiazolidinediones aim to restore sensitivity by targeting specific nodes such as AMPK or PPAR-gamma, thereby improving systemic glucose homeostasis [WebMD, MDPI]. Furthermore, emerging research highlights the role of these pathways in regulating inflammation and cellular proteostasis, suggesting broader implications for systemic health beyond glucose control [NIH, MDPI]. Understanding these pathways is critical for developing treatments for metabolic, cardiovascular, and neurodegenerative diseases [MDPI, NIH].

Other names

Insulin signaling pathwayInsulin action pathwayGlucose homeostasis pathwaysInsulin sensitivity network

Drugs targeting these pathways work through diverse mechanisms: biguanides like metformin activate AMPK and inhibit hepatic gluconeogenesis [NIH, StatPearls]; thiazolidinediones (TZDs) activate PPAR-gamma to enhance insulin sensitivity in muscle and fat [WebMD, StatPearls]; GLP-1 receptor agonists and DPP-4 inhibitors modulate the incretin system to stimulate glucose-dependent insulin secretion [NIH, MDPI]; and SGLT2 inhibitors promote urinary glucose excretion, indirectly improving sensitivity by reducing glucotoxicity [NIH].